HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LDS buys Kaolectrolyte, Prodium

This article was originally published in The Tan Sheet

Executive Summary

Cedar Rapids, Iowa-based LDS Consumer Products acquires U.S. marketing, distribution rights to Kaolectrolyte oral rehydration therapy for infants, children under six and Prodium urinary tract infection treatment from Requa, firm announces June 6. Kaolectrolyte competes against Ross' Pedialyte, while Prodium competitors include J&J's Uristat and PolyMedica's Azo-Standard; all three contain active phenazopyridine 95 mg. LDS obtained exclusive U.S. sales and marketing rights to Wartner Wart Removal System in 2002 (1"The Tan Sheet" April 28, 2003, p. 4)...

You may also be interested in...

Wartner Cryotherapy Product Looks To Freeze Wart Removal Competition

LDS Consumer Products' Wartner is the first OTC wart removal product featuring cryotherapy technology, according to the Cedar Rapids, Iowa-based firm

When A Single Shot Is A Problem: J&J’s Study Of Two Doses Raises Equality, Distribution Questions

FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.

Biohaven Shoots For Oral CGRP Leadership As Nurtec ODT Gains Momentum

The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts